Cervical infection with human papillomavirus (HPV) 6 or 11 in high-risk women in Burkina Faso

Sexually Transmitted Infections

Volumn 86, Issue 5, 2010, Pages 342-344

  Low, Andrea ^a   Didelot Rousseau, Marie Noelle ^b   Nagot, Nicolas ^a,b,c   Ouedraougo, Abdoulaye ^c   Clayton, Tim ^a   Konate, Issouf ^b   Van De Perre, Philippe ^b   Segondy, Michel ^b   Mayaud, Philippe ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b MONTPELLIER UNIVERSITY HOSPITAL   (France)

^c CENTRE MURAZ   (Burkina Faso)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; BURKINA FASO; CD4+ T LYMPHOCYTE; CONDYLOMA ACUMINATUM; FEMALE; GENOTYPE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 6; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RISK FACTOR; SEROPREVALENCE; SYPHILIS; UTERINE CERVIX; VAGINAL LAVAGE;

ADOLESCENT; ADULT; BURKINA FASO; CONDYLOMATA ACUMINATA; CROSS-SECTIONAL STUDIES; FEMALE; FOLLICULAR PHASE; HUMAN PAPILLOMAVIRUS 11; HUMAN PAPILLOMAVIRUS 6; HUMANS; MIDDLE AGED; PREVALENCE; RISK FACTORS; UTERINE CERVICAL DISEASES; VAGINAL DOUCHING; YOUNG ADULT;

EID: 77958032826     PISSN: 13684973     EISSN: 14723263     Source Type: Journal    
DOI: 10.1136/sti.2009.041053     Document Type: Article

References (11)

1. Castellsague X, Sanjose SD, Aguado T, et al. HPV and cervical cancer in the world: 2007 report. Vaccine 2007;25:C1-230.
2. Garland SM, Steben M, Sings HL, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis 2009;199:805-14.
3. Nagot N, Ouedraogo A, Ouangre A, et al. Is sexually transmitted infection management among sex workers still able to mitigate the spread of HIV infection in West Africa? J Acquir Immune Defic Syndr 2005;39:454-8.
4. Didelot-Rousseau MN, Nagot N, Costes-Martineau V, et al. Human papillomavirus genotype distribution and cervical squamous intraepithelial lesions among high-risk women with and without HIV-1 infection in Burkina Faso. Br J Cancer 2006;95:355-62.
5. Didelot-Rousseau MN, Courgnaud V, Nagot N, et al. Comparison of INNO-LiPA HPV Genotyping v2 with PCR product subcloning and sequencing for identification of genital human papillomavirus genotypes in African women. J Virol Methods 2006;135:181-5.
6. Mayaud P, Nagot N, Konate I, et al. Effect of HIV-1 and antiretroviral therapy on herpes simplex virus type 2: a prospective study in African women. Sex Transm Infect 2008;84:332-7.
7. Watts DH, Fazzari M, Minkoff H, et al. Effects of bacterial vaginosis and other genital infections on the natural history of human papillomavirus infection in HIV-1-infected and high-risk HIV-1-uninfected women. J Infect Dis 2005;191:1129-39.
8. Martino JL, Vermund SH. Vaginal douching: evidence for risks or benefits to women's health. Epidemiol Rev 2002;24:109-24.
9. Chen FC, Shaw SW, Cheng PJ, et al. Diagnosis of human papillomavirus infection by abnormal cervical cytology is highly reproducible after vaginal douching. Taiwan J Obstet Gynecol 2008;47:412-16.
10. La Ruche G, Messou N, Ali-Napo L, et al. Vaginal douching: association with lower genital tract infections in African pregnant women. Sex Transm Dis 1999;26:191-6.
11. Sonnex C. Influence of ovarian hormones on urogenital infection. Sex Transm Infect 1998;74:11-19.